Asset
ZALIFRELIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04607200 | phase2 | withdrawn | 2021-02-01 | 2021-09-13 | Agenus Inc. | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma |
| NCT03894215 | phase2 | terminated | 2019-06-01 | 2025-03-26 | Agenus Inc. | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer |
FDA applications (0)
This company has no applications containing this asset.